跳至主要内容
临床试验/NCT05058430
NCT05058430
已完成
不适用

SaliPen Human Factors Study for OTC Labeling

Saliwell Ltd.1 个研究点 分布在 1 个国家目标入组 24 人2021年9月16日
适应症Xerostomia

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Xerostomia
发起方
Saliwell Ltd.
入组人数
24
试验地点
1
主要终点
Percentage of Participants Who Appropriately Will Self-select the Study Product for Use Under Simulated OTC Conditions [Phase I]
状态
已完成
最后更新
2年前

概览

简要总结

This Human Factors Validation Testing will assess user interactions to verify the capability of potential users to assess if the study product fits their needs and if they can use it correctly based on the provided Information For User (IFU)?

More specifically, this is a non-comparative case series study and is subdivided into two major parts. Those parts are:

  1. Phase I: aimed at testing if, based on the IFU, the potential subjects can decide whether the study product is or is not appropriate to treat their condition and,
  2. Phase II: aimed at assessing whether the users can use the study product correctly without counseling by a health care provider.

详细描述

Phase I To simulate an OTC setting, potential subjects will be requested to read the label text on the outside of the study product package (external labeling) and determine whether the study product addresses their needs, without a provider direction or assistance. Phase II The study product will be dispensed only to those subjects who will indicate that they voluntarize to participate in this phase of the study. At Phase II subjects with xerostomia and that are willing to try the study product, will be requested to use it with no training, except for their understanding of the User Manual (internal labeling). Those subjects will use the study product in a supervised clinical setting. Subjects who report any discomfort will be offered the option to pause and remove the device upon such a request. Correct use verification will be performed by the study investigators. Subjects will answer questions regarding product use, clarity of the IFU, ease of use, etc. Subjects will also receive an exam of their oral cavity.

注册库
clinicaltrials.gov
开始日期
2021年9月16日
结束日期
2021年11月18日
最后更新
2年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
Saliwell Ltd.
责任方
Sponsor

入排标准

入选标准

  • For Phase I: 8 subjects with xerostomia and 8 without that are 18 years old or older For Phase II: Subjects with xerostomia that are 18 years old or older

排除标准

  • For Phase I:
  • Children and adolescents (persons under 18 years of age)
  • Persons with experience in the use of SaliPen
  • For Phase II: Subjects for them the study product is not indicated and/or do not agree to participate in Phase II. For the avoidance of doubt, the following conditions are exclusion criteria:
  • Persons with experience in the use of SaliPen
  • Children and adolescents (persons under 18 years of age)
  • Epileptic disorder
  • Persons that are allergic to the surface materials of the device
  • Electrodes: coated with gold
  • Body: made of methyl vinyl silicone rubber

结局指标

主要结局

Percentage of Participants Who Appropriately Will Self-select the Study Product for Use Under Simulated OTC Conditions [Phase I]

时间窗: One hour

Following the standard norms for the Rx-to-OTC switch process, this outcome is a validation of potential consumers' ability to self-diagnose the condition and to decide that treatment with the product is appropriate for them.

Percentage of Participants Who Correctly Will Use the Study Product When Dispensed Under Simulated OTC Conditions [Phase II].

时间窗: 1.5 hour

Correct use means that the participants will demonstrate the use of the study product according to the guidelines outlined in the User Manual. Following the standard norms for the therapy of Rx-to-OTC switch process, this outcome is a validation of potential consumers' ability to self-treat with the product according to the product's supplied IFU.

研究点 (1)

Loading locations...

相似试验